A synthetic long-acting cyclic peptide with somatostatin-like activity. Pasireotide activates a broad spectrum of somatostatin receptors, exhibiting a much higher binding affinity for somatostatin receptors 1, 3, and 5 than octreotide in vitro, as well as a comparable binding affinity for somatostatin receptor 2.This agent is more potent than somatostatin in inhibiting the release of human growth hormone (HGH), glucagon, and insulin. Check for active clinical trials using this agent. (NCI Thesaurus)
Related Posts
Recent Posts
